JUN
20

RECEIVED UPFRONT PAYMENT FROM NOVO NORDISK FOR EXCLUSIVE LICENSE AGREEMENT OF UBT251

APR
29

NOTICE OF ANNUAL GENERAL MEETING

APR
15

THE GROUP'S PRODUCT CEFOTAXIME SODIUM FOR INJECTION PASSED THE CONSISTENCY EVALUATION

APR
07

VOLUNTARY ANNOUNCEMENT PROPOSED SHARE BUY-BACK UNDER GENERAL MANDATE

MAR
26

Special dividend for the year ended 31 December 2024

MAR
25

Final dividend for the year ended 31 December 2024

MAR
24

2024 ANNUAL RESULTS ANNOUNCEMENT

MAR
24

VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT WITH NOVO NORDISK

MAR
21

UPDATED INFORMATION ON THE GROUP'S PRODUCT LIRAGLUTIDE INJECTION

MAR
21

UPDATED INFORMATION ON THE GROUP'S PRODUCT POLYVINYL ALCOHOL EYE DROPS

MAR
10

DATE OF BOARD MEETING

MAR
07

THE GROUP'S PRODUCT CEFTRIAXONE SODIUM FOR INJECTION PASSED THE CONSISTENCY EVALUATION

MAR
03

FDA APPROVAL OF IND FOR UBT251 INJECTION ON INDICATION OF CKD

JAN
22

APPROVAL FOR CLINICAL TRIAL OF UBT251 INJECTION ON INDICATION OF CHRONIC KIDNEY DISEASE

JAN
03

List of Directors and Their Role and Function